BioSpace News Archive

StageZero Life Sciences, Ltd. today announced further to its press releases of April 2, 2024, April 4, 2024, and April 9, 2024 that the Company remains under a Failure to File Cease Trade Order (“FFCTO”).

Evaxion Biotech A/S announces its participation in the American Society of Clinical Oncology Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study.

Mural Oncology plc, a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, shared data from ARTISTRY-3, a clinical trial designed to evaluate the effects of less frequent intravenous dosing of nemvaleukin alfa, in advance of the American Society of Clinical Oncology annual meeting taking place May 31-June 4 in Chicago.

On May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell carcinoma in an oral presentation at the 27th Annual Meeting of the American Society for Gene & Cell Therapy in Baltimore.

Medline announced the latest addition to its respiratory care portfolio, the Hudson RCI TurboMist small volume nebulizer.

Hornet Therapeutics, a biotech company focused on developing treatments to address EBV-driven pathologies, emerges from stealth with the publication of data in the prestigious journal Science, which reports IDO-1 as a host enzyme hijacked by EBV.

Harvard Bioscience, Inc. announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City on June 5, 2024.

AbbVie announced that it has completed its acquisition of Landos Biopharma, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor biology, announced that company management will participate in the following investor conferences.

Azenta, Inc. announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET.